Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2020

Pharma News, 2020

Five-year Zolgensma data shows SMA benefit
Five-year Zolgensma data shows SMA benefit
Novartis has released new Zolgensma (onasemnogene abeparvovec-xioi) data, demonstrating rapid, significant and clinically meaningful therapeutic benefit of the drug in patients with spinal mus...
Telemedicine reduces mental health burden of COVID-19
Telemedicine reduces mental health burden of COVID-19
New Rochelle, NY, March 23, 2020 --"The Role of Telehealth in Reducing the Mental Health Burden from COVID-19" has just been published in the peer-reviewed journal Telemedicine and e-Health.
Crumpled graphene makes ultra-sensitive cancer DNA detector
Crumpled graphene makes ultra-sensitive cancer DNA detector
Graphene-based biosensors could usher in an era of liquid biopsy, detecting DNA cancer markers circulating in a patient's blood or serum.
FDA dismisses Jardiance for type I diabetes
FDA dismisses Jardiance for type I diabetes
Eli Lilly and Boehringer Ingelheim have received a complete response letter from the US Food and Drug Administration (FDA) regarding the filing of Jardiance (empagliflozin) as an adjun...
OncoMX knowledgebase enables research of cancer biomarkers and related evidence
OncoMX knowledgebase enables research of cancer biomarkers and related evidence
WASHINGTON (March 23, 2020) -- The OncoMX knowledgebase will improve the exploration and research of cancer biomarkers in the context of related evidence, according to a recent article from th...
Using cannabinoids to treat acute pain
Using cannabinoids to treat acute pain
New Rochelle, NY, March 23, 2020 -- A new systematic review and meta-analysis showed a small but significant reduction in subjective pain scores for cannabinoid treatment compared to placebo in patien...
ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV
ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV
London, 20 March 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc.
Epizyme hires Kutok as CSO to find new uses for Tazverik
Epizyme hires Kutok as CSO to find new uses for Tazverik
Epizyme has appointed Jeffery Kutok as its chief scientific officer.
Janssen sends off NDA for new multiple sclerosis drug ponesimod
Janssen sends off NDA for new multiple sclerosis drug ponesimod
Johnson & Johnson has handed in its New Drug Application for its multiple sclerosis (MS) hopeful as it hopes to get in on this blockbuster market.
FDA OKs Gilead’s paediatric hep C drug
FDA OKs Gilead’s paediatric hep C drug
Gilead has announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Epclusa (sofosbuvir 400mg/velpatasvir 100mg; sofosbu...
Two generic drugs being tested in U.S. in race to find coronavirus treatments
Two generic drugs being tested in U.S. in race to find coronavirus treatments
(Reuters) - U.
Soligenix's stock climbs as phase 3 lymphoma trial hits goal
Soligenix's stock climbs as phase 3 lymphoma trial hits goal
A phase 3 trial of Soligenix’s cutaneous T-cell lymphoma treatment has squeezed under the bar for statistical significance.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand